Enlie Pharmaceutical JSC

Enlie Pharmaceutical JSC EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Enlie Pharmaceutical JSC (BCP.VN) as of Nov 1, 2026 is 96.73. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 14.01 — a change of 590.23% (higher).

EV/FCF

96.73

YoY

590.23%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Enlie Pharmaceutical JSC is 2024 96.73 . EV/FCF (Enterprise Value to Free Cash Flow) of Enlie Pharmaceutical JSC was 2023 14.01 . It decreases by 590.23% higher compared to the previous year.

The Enlie Pharmaceutical JSC EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
3.04 VND
Jan 1, 2018
6.55 VND
Jan 1, 2019
6.94 VND
Jan 1, 2020
-5.27 VND
Jan 1, 2021
-3.51 VND
Jan 1, 2022
-5.95 VND
Jan 1, 2023
14.01 VND
Jan 1, 2024
96.73 VND
The Enlie Pharmaceutical JSC EV/FCF history
YEAREV/FCFYoY
96.73+590.23%
14.01-335.40%
-5.95+69.40%
-3.51-33.35%
-5.27-175.92%
6.94+6.06%
6.55+115.55%
3.04-122.36%
-13.58-191.22%
14.89-153.08%
-28.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Enlie Pharmaceutical JSC Stock analysis

What does Enlie Pharmaceutical JSC do? Enlie Pharmaceutical JSC generates revenue primarily through the manufacture and commerce of pharmaceutical preparations, medical equipment, and health supplements. The company leverages its core expertise in these healthcare categories to serve the market, establishing its primary income streams around the production and sale of these essential health products. In addition to its pharmaceutical operations, the firm has diversified its business model by expanding into the real estate industry. This segment involves the development of various commercial and residential infrastructures which are then made available for lease, providing an additional layer of financial activity beyond its core healthcare focus. Enlie Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enlie Pharmaceutical JSC stock

EV/FCF (Enterprise Value to Free Cash Flow) of Enlie Pharmaceutical JSC is 96.73 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Enlie Pharmaceutical JSC changed from 14.01 to 96.73, representing a 590.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Enlie Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Enlie Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Enlie Pharmaceutical JSC

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Enlie Pharmaceutical JSC